Peptide Research
NAD+ Injections: The One on This List That Is Not a Peptide
NAD+ gets sold alongside research peptides and discussed in the same breath, but it is not a peptide at all. It is a coenzyme, and almost everything about how it behaves follows from that.
Peptide Library Editorial · February 17, 2026 · Updated August 30, 2026 · 3 min read

NAD+ is not a peptide. Nicotinamide adenine dinucleotide is a coenzyme — two nucleotides joined through phosphate groups — and it contains no amino acids at all.
It is sold by the same vendors, reconstituted the same way, and discussed in the same forums, which is why it ends up in peptide conversations. Almost everything distinctive about how it behaves follows from the fact that it is a different class of molecule entirely.
Not an approved drug in this form. Injectable NAD+ has no approved indication in the US, EU, or UK. It is sold for laboratory research only, and nothing here is dosing guidance.
What it actually does
NAD+ is a coenzyme involved in redox reactions across metabolism — it accepts and donates electrons, cycling between NAD+ and NADH. It is also a substrate consumed by enzymes including sirtuins and PARPs, which is where the interest in ageing comes from.
Cellular NAD+ levels decline with age, and that observation drives essentially all of the supplementation interest. Whether raising levels reverses anything associated with the decline is the open question the research is still working on.
Why the amounts are so much larger
This is the most immediately visible difference. Research peptides are dosed in micrograms to low milligrams; NAD+ is discussed in hundreds of milligrams.
Compound type | Typical vial | Typical discussed amount |
|---|---|---|
Research peptide | 5–10 mg | Micrograms to a few mg |
NAD+ | 500–1000 mg | Tens to hundreds of mg |
A coenzyme consumed stoichiometrically in metabolic reactions is not a signalling molecule binding a receptor at nanomolar concentrations. Different job, different scale.
The practical consequence is volume. A 500 mg vial needs substantially more diluent than any peptide vial, and the resulting solution volume is often more than one syringe barrel — which shapes how it can realistically be used.
Injection versus precursors
Most oral NAD+ products are not NAD+ but precursors — nicotinamide riboside or nicotinamide mononucleotide — because the intact molecule is poorly absorbed and is broken down before reaching cells.
Injection is intended to bypass that. What it does not bypass is the question of whether the intact molecule crosses cell membranes efficiently, which is a genuine open point in the literature rather than a settled advantage.
Subcutaneous NAD+ is also widely described as causing flushing, warmth, and injection-site discomfort, which is why intravenous administration in clinical settings is typically given slowly.
The vial math
NAD+ vials are large, and the diluent volumes follow.
Vial | BAC water | Concentration | 50 mg | 100 mg |
|---|---|---|---|---|
500 mg | 5 mL | 100 mg/mL | 50 units | 100 units |
500 mg | 10 mL | 50 mg/mL | 100 units | Over one barrel |
1000 mg | 10 mL | 100 mg/mL | 50 units | 100 units |
Note that a 10 mL reconstitution exceeds a standard 10 mL bacteriostatic water vial once you account for what is already in the vial, and produces far more solution than the 28-day window comfortably allows. The storage guide covers that constraint.
Storage
Storage is the same as any reconstituted vial: 2–8 °C, protected from light, never frozen, and bounded by the shorter of peptide stability and the 28-day limit on bacteriostatic water. The bacteriostatic water guide covers the detail.
Frequently asked questions
Is NAD+ a peptide?
No. It is a dinucleotide coenzyme with no amino acids. It is grouped with peptides by vendors, not by chemistry.
Is injection better than oral NMN or NR?
It bypasses digestive breakdown, which is the argument for it. Whether the intact molecule then reaches the intracellular compartment efficiently is not settled.
Why does it sting?
Flushing and injection-site discomfort are commonly described, which is why clinical intravenous administration is given slowly. It is a reported characteristic rather than a sign something has gone wrong.
Research and educational use only. Peptide Library is an independent research and comparison platform and does not sell peptides. Nothing here is medical advice, dosing guidance, or a recommendation to administer any substance to a person or an animal. Consult a licensed clinician for anything concerning human health.
Sources
Author
Peptide Library Editorial
Editorial content from Peptide Library. Research and educational use only. Not medical advice.
Related articles
Related peptides
Related tools
Research smarter with Peptide Library.
Compare peptides, review vendor data, and use research calculators in one place.
Explore the LibraryResearch and educational use only. Not medical advice. Peptide Library does not sell peptides.